NNC 45-1506
NNC 45-1506 is a chemical compound that has been studied for its potential effects on the central nervous system. It is primarily known for its role as a dopamine receptor agonist, which means it can bind to and activate dopamine receptors in the brain. This property makes it of interest in the study of neurological and psychiatric disorders where dopamine pathways are implicated, such as Parkinson's disease and schizophrenia.
Pharmacology[edit | edit source]
NNC 45-1506 acts as a selective agonist at certain subtypes of dopamine receptors. Dopamine receptors are a class of G protein-coupled receptors that are divided into D1-like and D2-like families. The specific binding affinity and selectivity of NNC 45-1506 for these receptor subtypes can influence its pharmacological effects.
Mechanism of Action[edit | edit source]
The mechanism of action of NNC 45-1506 involves the activation of dopamine receptors, which leads to a cascade of intracellular events. This activation can result in increased levels of cyclic adenosine monophosphate (cAMP) in neurons, which is a secondary messenger involved in many biological processes. By modulating dopamine receptor activity, NNC 45-1506 can influence neurotransmission and neuronal excitability.
Research and Development[edit | edit source]
NNC 45-1506 has been the subject of various preclinical studies to evaluate its potential therapeutic applications. Research has focused on its effects in animal models of neurological disorders. These studies aim to understand its efficacy, safety, and pharmacokinetic properties.
Potential Therapeutic Uses[edit | edit source]
- Parkinson's Disease: As a dopamine receptor agonist, NNC 45-1506 may help alleviate symptoms of Parkinson's disease by compensating for the loss of dopaminergic neurons.
- Schizophrenia: Dopamine dysregulation is a key feature of schizophrenia, and NNC 45-1506 could potentially modulate this pathway to improve symptoms.
Safety and Side Effects[edit | edit source]
The safety profile of NNC 45-1506 is still under investigation. Common side effects associated with dopamine agonists include nausea, dizziness, and orthostatic hypotension. Long-term effects and potential toxicity need further study.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
